TAMPA, Fla., Dec. 10, 2017 /PRNewswire/ — A new article published today in The New England Journal of Medicine shows that 42 percent of diffuse large B cell lymphoma patients treated with axicabtagene ciloleucel, offered commercially under the brand name Yescarta™, remain in remission 15…
